{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:32:05Z","timestamp":1793637125660,"version":"4.5.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-242209-BIOSTAT-CHF"],"award-info":[{"award-number":["FP7-242209-BIOSTAT-CHF"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EudraCT 2010-020808-29"],"award-info":[{"award-number":["EudraCT 2010-020808-29"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice. This study aims to describe the determinants and pattern of use of MRAs in HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>BIOSTAT-CHF is a European multicentre, prospective study which enrolled patients suboptimally treated with angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEi\/ARBs) and\/or beta-blockers, with the aim of optimizing guideline-based use of these agents. From the original 2516 subjects, this retrospective post hoc analysis included the 1325 patients with an indication for MRA therapy (i.e. left ventricular ejection fraction \u226435%, estimated glomerular filtration rate \u226530 mL\/min\/1.73\u2009m2, K+ \u22645.0\u2009mmol\/L). The mean age was 66.1\u2009\u00b1\u200912.2\u2009years. At baseline an MRA was prescribed to 741 (56%) patients. Patients who were prescribed MRAs at baseline were younger, more often male, had higher body mass index, lower sodium, higher proportion of hypertension history and ACEi\/ARB prescription (all P &amp;lt; 0.05). Of the 1049 patients who completed the baseline plus the 9 month visit, 585 (56%) had an MRA prescribed at baseline and 662 (63%) had an MRA prescribed at 9 months. Among the 585 patients with MRA at baseline, 91 (16%) had discontinued therapy and among the 461 (44%) patients without MRA at baseline 168 (36%) had initiated therapy subsequently. MRA discontinuation was more likely in subjects with higher left ventricular ejection fraction and NYHA class III\/IV (P &amp;lt; 0.05 for both). MRA prescription both at baseline and 9 months was not associated with the outcome of death or heart failure hospitalization (adjusted hazard ratio 1.02, 95% confidence interval 0.66\u20131.58; P\u2009=\u20090.93).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this prospective observational study across Europe, MRAs were largely under-prescribed and frequently discontinued. Owing to these dynamic changes, outcome inferences are inconclusive.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.900","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T03:18:45Z","timestamp":1496632725000},"page":"1284-1293","source":"Crossref","is-referenced-by-count":97,"title":["Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF"],"prefix":"10.1093","volume":"19","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, Universit\u00e9 de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT , Nancy ,","place":["France"]},{"name":"Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, Universit\u00e9 de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Loup","family":"Machu","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, Universit\u00e9 de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC ,","place":["USA"]},{"name":"Mazankowski Alberta Heart Institute, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, Universit\u00e9 de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Innovative Clinical Trials, University Medical Centre G\u00f6ttingen (UMG), Robert-Koch-Stra\u00dfe , D-37075, G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[{"name":"University of Bergen , Bergen ,","place":["Norway"]},{"name":"Stavanger University Hospital , Stavanger ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kopodistrian University of Athens, School of Medicine, Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon , Rimini 1, Athens, 12462 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L.","family":"Hillege","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1 , 9713, GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C.","family":"Lang","sequence":"additional","affiliation":[{"name":"Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozine M.","family":"ter Maaten","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1 , 9713, GZ, Groningen ,","place":["The Netherlands"]},{"name":"Program of Applied Translational Research, Yale University , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester, UK and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, Wroclaw, Poland and Department of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh J.","family":"Samani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, BHF Cardiovascular Research Centre, Glenfield Hospital, Groby Rd , Leicester, LE3 9QP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1 , 9713, GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[{"name":"Academic Medical Center, Clinical Epidemiology Biostatistics and Bioinformatics , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1 , 9713, GZ, Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, Universit\u00e9 de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"2026011721200303500_ejhf900-bib-0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721200303500_ejhf900-bib-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721200303500_ejhf900-bib-0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026011721200303500_ejhf900-bib-0004","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"2026011721200303500_ejhf900-bib-0005","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ahj.2011.01.027","article-title":"Potential impact of optimal implementation of evidence-based heart failure therapies on mortality","volume":"161","author":"Fonarow","year":"2011","journal-title":"Am Heart J"},{"key":"2026011721200303500_ejhf900-bib-0006","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijcard.2014.11.004","article-title":"Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries","volume":"177","author":"Rossignol","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2016.07.032","article-title":"Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia","volume":"118","author":"Pitt","year":"2016","journal-title":"Pharmacol Res"},{"key":"2026011721200303500_ejhf900-bib-0008","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.jacc.2010.07.013","article-title":"Heart failure guidelines, performance measures, and the practice of medicine: mind the gap","volume":"56","author":"Ghali","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0009","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijcard.2014.02.034","article-title":"Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study","volume":"173","author":"Rossignol","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0011","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0012","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0013","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011721200303500_ejhf900-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002268","article-title":"Temporal trends and hospital variation in mineralocorticoid receptor antagonist use in veterans discharged with heart failure","volume":"4","author":"Dev","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026011721200303500_ejhf900-bib-0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-11-4","article-title":"Use, tolerability and compliance of spironolactone in the treatment of heart failure","volume":"11","author":"Lachaine","year":"2011","journal-title":"BMC Clin Pharmacol"},{"key":"2026011721200303500_ejhf900-bib-0016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MJT.0b013e3181ea3213","article-title":"Adherence to aldosterone-blocking agents in patients with heart failure","volume":"17","author":"Margolis","year":"2010","journal-title":"Am J Ther"},{"key":"2026011721200303500_ejhf900-bib-0017","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"2026011721200303500_ejhf900-bib-0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijcard.2016.11.006","article-title":"Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone","volume":"227","author":"Lam","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0019","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0021","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011721200303500_ejhf900-bib-0022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026011721200303500_ejhf900-bib-0023","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0024","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026011721200303500_ejhf900-bib-0025","doi-asserted-by":"crossref","first-page":"H1126","DOI":"10.1152\/ajpheart.00898.2014","article-title":"Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice","volume":"308","author":"Bostick","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721200303500_ejhf900-bib-0026","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from EMPHASIS-HF trial","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0027","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.814","article-title":"Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0028","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","article-title":"EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"12","author":"Maggioni","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0029","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","article-title":"Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure","volume":"165","author":"Curtis","year":"2013","journal-title":"Am Heart J"},{"key":"2026011721200303500_ejhf900-bib-0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","article-title":"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998\u20132001","volume":"112","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"2026011721200303500_ejhf900-bib-0031","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0032","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2026011721200303500_ejhf900-bib-0033","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0034","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/clc.4960290405","article-title":"Use and side-effect profile of spironolactone in a private cardiologist's practice","volume":"29","author":"Williams","year":"2006","journal-title":"Clin Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0036","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.11904","article-title":"Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"314","author":"Cooper","year":"2015","journal-title":"JAMA"},{"key":"2026011721200303500_ejhf900-bib-0037","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2026011721200303500_ejhf900-bib-0038","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ncpcardio0914","article-title":"Drug insight: aldosterone-receptor antagonists in heart failure\u2014the journey continues","volume":"4","author":"Kalidindi","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2026011721200303500_ejhf900-bib-0039","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.116.022922","article-title":"DENERHTN Investigators. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the Renal Denervation for Hypertension (DENERHTN) trial","volume":"134","author":"Azizi","year":"2016","journal-title":"Circulation"},{"key":"2026011721200303500_ejhf900-bib-0041","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ejheart.2008.08.001","article-title":"Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDress your Heart survey","volume":"10","author":"Erhardt","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0042","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002493","article-title":"Barriers to adoption of mineralocorticoid receptor antagonists in patients with heart failure: a mixed-methods study","volume":"5","author":"Dev","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026011721200303500_ejhf900-bib-0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0044","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721200303500_ejhf900-bib-0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1751-7133.2011.00250.x","article-title":"Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF","volume":"18","author":"Gheorghiade","year":"2012","journal-title":"Congest Heart Fail"},{"issue":"11 Suppl","key":"2026011721200303500_ejhf900-bib-0046","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2026011721200303500_ejhf900-bib-0047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pds.1217","article-title":"Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers","volume":"16","author":"Raebel","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026011721200303500_ejhf900-bib-0048","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.ijcard.2013.05.090","article-title":"Effectiveness of a multidimensional home nurse led heart failure disease management program\u2014a French nationwide time-series comparison","volume":"168","author":"Agrinier","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721200303500_ejhf900-bib-0049","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ahj.2011.09.019","article-title":"A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure","volume":"162","author":"Postmus","year":"2011","journal-title":"Am Heart J"},{"key":"2026011721200303500_ejhf900-bib-0050","first-page":"CD002752","article-title":"Clinical service organisation for heart failure","volume":"9","author":"Takeda","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/10\/1284\/66327813\/eurjhf_19_10_1284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/10\/1284\/66327813\/eurjhf_19_10_1284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:22:20Z","timestamp":1768702940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/10\/1284\/8418515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,6,5]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.900","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,6,5]]}}}